AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 26, 2020 GMT

SAN DIEGO--(BUSINESS WIRE)--Feb 26, 2020--

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2019.

“In 2019 ACADIA demonstrated strong execution from our commercial and R&D teams, driving the continued growth of NUPLAZID and advancing our late-stage pipeline,” said Steve Davis, Chief Executive Officer. “2020 will be a transformational year for ACADIA highlighted by a potential approval in dementia-related psychosis, additional pivotal study results in major depressive disorder, commencement of a second pivotal study for the negative symptoms of schizophrenia and the continued enrollment of the Phase 3 trofinetide study for Rett syndrome. This exciting momentum has created a multi-year cadence of pivotal study readouts and potential regulatory approvals that position the company for long-term growth.”

Company Highlights

  • Presented positive top-line results from the Phase 3 HARMONY study of pimavanserin for the treatment of dementia-related psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting on December 4, 2019.
    • The Company plans to submit a supplemental NDA for pimavanserin for the treatment of dementia-related psychosis in the summer of 2020. Pimavanserin previously received Breakthrough Therapy Designation for this indication.

  • Announced positive top-line results from the pivotal Phase 2 ADVANCE study of pimavanserin for the negative symptoms of schizophrenia in November 2019.
    • The Company plans to initiate a second pivotal study, ADVANCE-2, of pimavanserin for the negative symptoms of schizophrenia during the summer of 2020.

  • The Company expects to announce top-line results from its Phase 3 CLARITY-2 study of pimavanserin as an adjunctive treatment for major depressive disorder in the fourth quarter of 2020.

  • Appointed Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer and Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer.

Financial Results

Revenue

Net sales of NUPLAZID ® (pimavanserin) were $98.3 million for the fourth quarter of 2019, an increase of 65% as compared to $59.6 million reported for the fourth quarter of 2018. End of fourth quarter days-on-hand channel inventory increased relative to the third quarter 2019, which resulted in approximately $2.5 million increase in fourth quarter 2019 net sales. For the years ended December 31, 2019 and 2018, ACADIA reported net product sales of $339.1 million and $223.8 million, respectively, an increase of 52% year-over-year.

Research and Development

Research and development expenses for the fourth quarter of 2019 were $57.5 million, compared to $48.2 million for the same period of 2018. For the years ended December 31, 2019 and 2018, research and development expenses were $240.4 million and $187.2 million, respectively. The increase during the 2019 periods as compared to 2018 was primarily due to development costs associated with trofinetide and additional clinical study costs for pimavanserin.

Selling, General and Administrative

Selling, general and administrative expenses for the fourth quarter of 2019 were $91.9 million, compared to $74.3 million for the same period of 2018. For the years ended December 31, 2019 and 2018, selling, general and administrative expenses were $325.6 million and $265.8 million, respectively. This increase during the 2019 periods as compared to 2018 was primarily due to increased general and administrative expenses including charitable contributions and personnel costs.

Net Loss

For the fourth quarter of 2019, ACADIA reported a net loss of $53.0 million, or $0.34 per common share, compared to a net loss of $65.5 million, or $0.50 per common share, for the same period in 2018. The net losses for the fourth quarters of 2019 and 2018 included $19.8 million and $20.4 million, respectively, of non-cash stock-based compensation expense. For the years ended December 31, 2019, ACADIA reported a net loss of $235.3 million, or $1.60 per common share, compared to a net loss of $245.2 million, or $1.94 per common share, for the same period in 2018. The net losses for the years ended December 31, 2019 and 2018 included $82.2 million and $81.6 million, respectively, of non-cash stock-based compensation expense.

Cash and Investments

At December 31, 2019, ACADIA’s cash, cash equivalents, and investment securities totaled $697.4 million, compared to $473.5 million at December 31, 2018. The increase was primarily due to net proceeds of $271.5 million from ACADIA’s September 2019 public offering of common stock as well as additional cash proceeds from employee option exercises of $91.6 million.

2020 Financial Guidance

ACADIA’s 2020 net sales guidance reflects annual revenue growth of approximately 34% for NUPLAZID, at the mid-point of the range. 2020 GAAP R&D guidance reflects the progression of four phase 3 studies this year. 2020 GAAP SG&A guidance reflects a similar level of investment to 2019 in PDP with new investments in preparing for a launch in DRP including disease-state educational initiatives and plans for the expansion of our commercial and medical affairs functions.

  • NUPLAZID net sales are expected to be between $440 and $470 million.
  • GAAP R&D is expected to be between $270 and $285 million.
  • GAAP SG&A is expected to be between $440 and $460 million.
  • Non-cash stock-based compensation expense is expected to be between $90 and $100 million.
  • 2020 year-end cash, cash equivalents, and investment securities are expected to be between $470 and $500 million.

Conference Call and Webcast Information

ACADIA management will review its fourth quarter and full year 2019 financial results and operations via conference call and webcast today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 855-638-4820 for participants in the U.S. or Canada and 443-877-4067 for international callers (reference passcode 6692587 ). A telephone replay of the conference call may be accessed through March 11, 2020 by dialing 855-859-2056 for callers in the U.S. or Canada and 404-537-3406 for international callers (reference passcode 6692587 ). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there through March 26, 2020.

About NUPLAZID ® (pimavanserin)

NUPLAZID is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting 5-HT 2A receptors that are thought to play an important role in Parkinson’s disease psychosis. NUPLAZID is an oral medicine taken once a day with a recommended dose of 34 mg. NUPLAZID is not FDA-approved for dementia-related psychosis, schizophrenia, major depressive disorder, or depressive symptoms in patients with Parkinson’s disease. ACADIA discovered and developed this new chemical entity and holds worldwide rights to develop and commercialize NUPLAZID.

About Trofinetide

Trofinetide is an investigational drug. It is a novel synthetic analog of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function. In the central nervous system, IGF-1 is produced by both of the major types of brain cells – neurons and glia. IGF-1 in the brain is critical for both normal development and for response to injury and disease. Trofinetide has been granted Fast Track Status and Orphan Drug Designation in the U.S. and Orphan Drug Designation in Europe for both Rett syndrome and Fragile X syndrome.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, the negative symptoms of schizophrenia, major depressive disorder, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: the potential opportunity for future growth in sales of NUPLAZID; the timing of ongoing and future clinical studies for pimavanserin; the development and commercialization of trofinetide; and guidance for full-year 2020 NUPLAZID net sales and certain expense line items. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the uncertainty of future commercial sales and related items that would impact net sales during 2020, the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2018 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended December 31,

 

Years Ended December 31,

 

 

2019

 

2018

 

2019

 

2018

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

98,326

 

 

$

59,571

 

 

$

339,076

 

 

$

223,807

 

Total revenues

 

 

98,326

 

 

 

59,571

 

 

 

339,076

 

 

 

223,807

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales, license fees and royalties (1)

 

 

5,334

 

 

 

4,392

 

 

 

19,598

 

 

 

18,330

 

Research and development (1)

 

 

57,520

 

 

 

48,183

 

 

 

240,385

 

 

 

187,163

 

Selling, general and administrative (1)

 

 

91,871

 

 

 

74,271

 

 

 

325,638

 

 

 

265,758

 

Total operating expenses

 

 

154,725

 

 

 

126,846

 

 

 

585,621

 

 

 

471,251

 

Loss from operations

 

 

(56,399

)

 

 

(67,275

)

 

 

(246,545

)

 

 

(247,444

)

Interest income, net

 

 

3,272

 

 

 

1,670

 

 

 

11,165

 

 

 

5,348

 

Other expense

 

 

491

 

 

 

127

 

 

 

997

 

 

 

(1,840

)

Loss before income taxes

 

 

(52,636

)

 

 

(65,478

)

 

 

(234,383

)

 

 

(243,936

)

Income tax expense

 

 

400

 

 

 

14

 

 

 

876

 

 

 

1,256

 

Net loss

 

$

(53,036

)

 

$

(65,492

)

 

$

(235,259

)

 

$

(245,192

)

Net loss per common share, basic and diluted

 

$

(0.34

)

 

$

(0.50

)

 

$

(1.60

)

 

$

(1.94

)

Weighted average common shares outstanding, basic and diluted

 

 

154,492

 

 

 

131,627

 

 

 

147,199

 

 

 

126,583

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Includes the following share-based compensation expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales, license fees and royalties

 

$

592

 

 

$

838

 

 

$

2,936

 

 

$

3,863

 

Research and development

 

$

8,072

 

 

$

8,421

 

 

$

32,533

 

 

$

32,038

 

Selling, general and administrative

 

$

11,099

 

 

$

11,142

 

 

$

46,796

 

 

$

45,663

 

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

 

 

December 31,

2019

 

 

December 31,

2018

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Cash, cash equivalents and investment securities

 

$

697,429

 

 

$

473,520

 

Accounts receivable, net

 

 

35,781

 

 

 

26,090

 

Interest and other receivables

 

 

2,093

 

 

 

1,699

 

Inventory

 

 

6,341

 

 

 

4,070

 

Prepaid expenses

 

 

18,606

 

 

 

20,727

 

Total current assets

 

 

760,250

 

 

 

526,106

 

Property and equipment, net

 

 

3,180

 

 

 

3,309

 

Operating lease right-of-use assets

 

 

9,524

 

 

 

 

Intangible assets, net

 

 

2,585

 

 

 

4,062

 

Restricted cash

 

 

4,787

 

 

 

4,826

 

Other assets

 

 

2,857

 

 

 

1,899

 

Total assets

 

$

783,183

 

 

$

540,202

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Accounts payable

 

$

7,222

 

 

$

3,167

 

Accrued liabilities

 

 

67,604

 

 

 

56,398

 

Total current liabilities

 

 

74,826

 

 

 

59,565

 

Operating lease liabilities

 

 

6,361

 

 

 

 

Long-term liabilities

 

 

2,861

 

 

 

1,558

 

Total liabilities

 

 

84,048

 

 

 

61,123

 

Total stockholders’ equity

 

 

699,135

 

 

 

479,079

 

Total liabilities and stockholders’ equity

 

$

783,183

$

540,202

 

 

View source version on businesswire.com:https://www.businesswire.com/news/home/20200226005906/en/

CONTACT: Media Contact:

ACADIA Pharmaceuticals Inc.

Stephanie Fagan

(858) 212-0534

media@acadia-pharm.comInvestor Contact:

ACADIA Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH MENTAL HEALTH

SOURCE: ACADIA Pharmaceuticals Inc.

Copyright Business Wire 2020.

PUB: 02/26/2020 04:05 PM/DISC: 02/26/2020 04:05 PM

http://www.businesswire.com/news/home/20200226005906/en